The initial public offering (IPO) of Accretion Nutraveda, which commenced bidding today, January 28, has encountered a notably lukewarm reception from the investment community. As of noon, the issue was subscribed a mere 0.01 times, reflecting significant investor caution. Bids were received for only 15,000 shares against the total offering of 12.80 lakh shares available for subscription.
Utilization of IPO Proceeds
The company has outlined its intention to allocate the net proceeds from this public offering towards meeting its working capital requirements and for general corporate purposes. This strategic move is aimed at bolstering operational efficiency and supporting future growth initiatives.
Detailed Accretion Nutraveda IPO Specifications
Subscription Timeline and Pricing
The subscription window for the Accretion Nutraveda IPO opened today, January 28, and is scheduled to remain accessible to investors until Friday, January 30. The price band for the equity shares has been firmly set between ₹122 and ₹129 per share.
Financial Objectives and Structure
Through this public offering, Accretion Nutraveda aims to secure approximately ₹24.77 crore. This capital will be raised via a fresh issue comprising 0.19 crore shares. The lot size for the IPO is established at 2,000 shares, which translates to a minimum investment threshold of ₹2.58 lakh for retail investors.
Investor Allocation and Key Dates
The IPO has strategically reserved shares for different investor categories:
- Qualified Institutional Buyers (QIB): 9.08 lakh shares
- Non-Institutional Investors (NII): 2.76 lakh shares
- Retail Investors: 6.40 lakh shares
Listing and Market Indicators
This SME IPO is proposed to be listed on the BSE SME platform on Wednesday, February 04. Notably, the grey market premium (GMP) for the Accretion Nutraveda IPO was reported at zero on Wednesday, suggesting a potential listing at or very close to the IPO issue price, indicating muted pre-listing speculative interest.
Oversight and Company Profile
Sobhagya Capital Options Pvt. Ltd. is serving as the book-running lead manager for this issue, with Kfin Technologies Ltd. acting as the registrar. The market maker for the company is Sunflower Broking Pvt. Ltd. Accretion Nutraveda is primarily engaged in the manufacturing of Ayurvedic and nutraceutical products. Its diverse portfolio includes various dosage forms such as tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels.
Investors are strongly advised to consult with certified financial experts and conduct thorough due diligence before making any investment decisions related to this or any other public offering.
